Drs J.L. Gulikers

Gulikers, J. L., Otten, L.-S., Hendriks, L. E. L., Winckers, K., Henskens, Y., Leentjens, J., van den Heuvel, M. M., Ter Heine, R., Croes, S., Piet, B., & van Geel, R. M. J. M. (2024). Proactive monitoring of drug-drug interactions between direct oral anticoagulants and small-molecule inhibitors in patients with non-small cell lung cancer. British Journal of Cancer, 131(3), 481-490. https://doi.org/10.1038/s41416-024-02744-1

Gulikers, J. L., Veerman, G. D. M., Jebbink, M., Kruithof, P. D., Steendam, C. M. J., Boosman, R. J., Mathijssen, R. H. J., Tjan-Heijnen, V. C. G., Driessen, J. H. M., Dursun, S., Smit, E. F., Dingemans, A. M. C., van Geel, R. M. J. M., Croes, S., & Hendriks, L. E. L. (2024). Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC. JTO Clinical and Research Reports, 5(4), Article 100656. https://doi.org/10.1016/j.jtocrr.2024.100656

van Veelen, A., Veerman, G. D. M., Verschueren, M. V., Gulikers, J. L., Steendam, C. M. J., Brouns, A. J. W. M., Dursun, S., Paats, M. S., Tjan-Heijnen, V. C. G., van der Leest, C., Dingemans, A.-M. C., Mathijssen, R. H. J., van de Garde, E. M. W., Souverein, P., Driessen, J. H. M., Hendriks, L. E. L., van Geel, R. M. J. M., & Croes, S. (2024). Exploring the impact of patient-specific clinical features on osimertinib effectiveness in a real-world cohort of patients with EGFR mutated non-small cell lung cancer. International Journal of Cancer, 154(2), 332-342. https://doi.org/10.1002/ijc.34742

Gulikers, J., Bruinsma, J., Schoenmaekers, J., Dursun, S., Tjan-Heijnen, V., van Geel, R., Croes, S., & Hendriks, L. (2024). Patient perspectives on treatment-related toxicities and therapeutic drug monitoring with tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer. Therapeutic Advances in Medical Oncology, 16. https://doi.org/10.1177/17588359241303403

Kruithof, P. D., de Beer, Y. M., Gulikers, J. L., Stolk, L. M. L., Hendriks, L. E. L., Croes, S., & van Geel, R. M. J. M. (2023). Validated extended multiplexed LC-MS/MS assay for the quantification of adagrasib and sotorasib in human plasma, together with four additional SMIs. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1231(1), Article 123918. https://doi.org/10.1016/j.jchromb.2023.123918

Gulikers, J. L., van Veelen, A. J., Driessen, J. H. M., Souverein, P. C., Tjan-Heijnen, V. C. G., Hendriks, L. E. L., van Geel, R. M. J. M., & Croes, S. (2023). Comparison of characteristics of patients with lung cancer in UK primary care databases: Clinical Practice Research Datalink Aurum and GOLD. Pharmacoepidemiology and Drug Safety, 32(10), 1161-1177. https://doi.org/10.1002/pds.5637

Verschueren, M. V., Dijs, T., Gulikers, J. L., van Veelen, A., Croes, S., Hendriks, L. E. L., Smit, A. A. J., Bloem, L. T., Egberts, A. C. G., van de Garde, E. M. W., & Peters, B. J. M. (2023). Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results. Immunotherapy, 15(11), 839-851. https://doi.org/10.2217/imt-2023-0002

Gulikers, J. L., van Veelen, A. J., Sinkiewicz, E. M. J., de Beer, Y. M., Slikkerveer, M., Stolk, L. M. L., Tjan-Heijnen, V. C. G., Hendriks, L. E. L., Croes, S., & van Geel, R. M. J. M. (2023). Development and validation of an HPLC-MS/MS method to simultaneously quantify brigatinib, lorlatinib, pralsetinib and selpercatinib in human K2-EDTA plasma. Biomedical Chromatography, 37(6), Article e5628. https://doi.org/10.1002/bmc.5628

Gulikers, J. L., Slikkerveer, M., Winckers, K., Hendriks, L. E. L., Dursun, S., Croes, S., & van Geel, R. M. J. M. (2022). Case report: Drug-drug interaction between alectinib and apixaban in NSCLC. Current Problems in Cancer: Case Reports, 7, Article 100186. https://doi.org/10.1016/j.cpccr.2022.100186